The trial investigators respond to their numerous critics
If you've been reading about ORBITA, then you probably know that the first ever placebo-controlled trial of percutaneous coronary intervention (PCI) was interesting and provocative. But you've also probably heard that the trial was too small, too short, and performed in patients who should not have been studied. Simultaneously, you also probably heard from the same critics that the trial both reaffirmed what interventional cardiologists already knew and were already doing. So the message was that it was a bad trial, except for the fact that it confirmed the obvious.